{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Fran\u00e7ois GUILLONNEAU"}, {"accession": "MS:1000589", "name": "contact email", "value": "francois.guillonneau@parisdescartes.fr"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "3P5 Universit\u00e9 Paris Descartes"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Didier Bouscary"}, {"accession": "MS:1000589", "name": "contact email", "value": "didier.bouscary@aphp.fr"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Service d\u2019h\u00e9matologie Clinique et biologique, H\u00f4pital Cochin, Paris. Universit\u00e9 de Paris, Institut Cochin, Inserm U1016, D\u00e9partement D\u00e9veloppement, Reproduction, Cancer, Centre National de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 8104 Paris"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/PaMA160401_E2_IP1_F14844.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/PaMA160401_E2_IP2_F14846.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/PaMA160401_E2_total_F14848.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/PaMA160401_E3_IP1_F14845.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/PaMA160401_E3_IP2_F14847.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/PaMA160401_E3_total_F14849.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/mqparSilacK8R10PhosphoSTYmq15330.xml"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839/MaxQuant_Output.zip"}], "description": "Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. Vacuolar protein sorting 34 (VPS34) is a member of the phosphatidylinositol-3-kinase lipid kinase family that controls the canonical autophagy pathway and vesicular trafficking. Using a recently developed specific inhibitor (VPS34-IN1), we found that a VPS34 block induces apoptosis in AML cells but not in normal CD34+ hematopoietic cells. Complete and acute inhibition of VPS34 was required for the anti-leukemic activity of VPS34-IN1. This inhibitor also has pleiotropic effects against various cellular functions related to class III PI3K in AML cells that may explain their survival impairment. VPS34-IN1 inhibits basal and L-asparaginase-induced autophagy in AML cells. A synergistic cell death activity of this drug was also demonstrated. VPS34-IN1 was additionally found to impair vesicular trafficking and mTORC1 signaling. From an unbiased approach based on phosphoproteomic analysis, we identified that VPS34-IN1 specifically inhibits STAT5 phosphorylation downstream of FLT3-ITD signaling in AML. The identification of the mechanisms controlling FLT3-ITD signaling by VPS34 represents an important insight into the oncogenesis of AML and could lead to new therapeutic strategies.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD016839"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD016839"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD016839"}], "instruments": [{"accession": "MS:1000449", "name": "LTQ Orbitrap"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Orbitrap fusion, human MOLM-14 cells, VPS34, VPS34-IN1, AML, L-asparaginase, autophagy"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "33093450"}, {"accession": "MS:1002866", "name": "Reference", "value": "Meunier G, Birsen R, Cazelles C, Belhadj M, Cantero-Aguilar L, Kosmider O, Fontenay M, Azar N, Mayeux P, Chapuis N, Tamburini J, Bouscary D. Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis. 2020 9(10):94"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia"}